Compounds > thymocartin
Page last updated: 2024-11-10

thymocartin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3033954
CHEMBL ID2104516
SCHEMBL ID443972
MeSH IDM0133016

Synonyms (28)

Synonym
thymocartin
rgh-0206
thymocartinum [inn-latin]
thymocartin [inn]
thymocartina [inn-spanish]
rgh 0206
n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)-l-valine
thymocartine [inn-french]
l-valine, n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)-
l-valine, n-(n-(n2-l-arginyl-l-lysyl)-l-alpha-aspartyl)-
CHEMBL2104516
h-arg-lys-asp-val-oh
thymocartine
m0h0sk3ad5 ,
thymocartinum
thymocartina
unii-m0h0sk3ad5
85466-18-8
n-(n-(n2-l-arginyl-l-lysyl)-l-.alpha.-aspartyl)-l-valine
SCHEMBL443972
DTXSID20234688
(6s,9s,12s,15s)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-1-imino-15-isopropyl-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-oic acid
rgh 0206; tp 4
Q27283305
(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
HY-105025
CS-0024724
AKOS040754200

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" toxicity test on Wobe:BEAGLE dogs given daily doses of 6, 20 and 60 mg/kg of either test compound, no adverse reaction occurred."( Preclinical toxicity studies with two thymopoietin-like peptides.
Bodrogligeti, I; Cholnoky, E; Iván, E; Juhász-Nagy, A; Német, L, 1985)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (29.41)18.7374
1990's8 (47.06)18.2507
2000's2 (11.76)29.6817
2010's1 (5.88)24.3611
2020's1 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sb 202190
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase		2.2510imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.3720naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		1.9810aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
mannitol
[no description available]		210mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		1.9810arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
trifluoroethanol
Trifluoroethanol: A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.		1.9810fluoroalcohol
lentinan
[no description available]		1.9710
splenotritin
[no description available]		2.3720oligopeptide
thymopentin
Thymopentin: Synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. It is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, AIDS, and other primary immunodeficiencies.		2.6630oligopeptide
oxazolone
Oxazolone: Immunologic adjuvant and sensitizing agent.		1.9610
rgh 0205
RGH 0205: RN given refers to all (L)-isomer		2.8940oligopeptide
vx-745
[no description available]		2.2510aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		1.9810
mannans
[no description available]		2.3820
ConditionIndicatedRelationship StrengthStudiesTrials
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.2510
Astrocytoma, Grade IV
[description not available]		02.2510
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.2510
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1110
Infections, Helicobacter
[description not available]		02.1110
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.1110
Armstrong Syndrome
[description not available]		02.3820
Metastase
[description not available]		01.9710
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		01.9710
Delayed Hypersensitivity
[description not available]		02.3720
Cancer of Lung
[description not available]		01.9710
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9710
Acute Liver Injury, Drug-Induced
[description not available]		01.9610
Eye Disorders
[description not available]		01.9610
Blood Diseases
[description not available]		01.9610
Nervous System Disorders
[description not available]		01.9610
Eye Diseases
Diseases affecting the eye.		01.9610
Hematologic Diseases
Disorders of the blood and blood forming tissues.		01.9610
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9610
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		01.9610
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		01.9610